CoChat

Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Background Nivolumab, an anti-programmed death-1 (PD-1) antibody, is administered in patients with previously treated non-small cell lung cancer. However, little is known about the established biomarker predicting the efficacy of nivolumab. Here, we conducted a preliminary study to investigate whether 18 F-FDG-PET/CT could predict the therapeutic response of nivolumab at the early phase. Methods Twenty-four patients were enrolled in this study. 18 F-FDG-PET/CT was carried out before and 1 month after nivolumab therapy. SUV max , metabolic tumour volume (MTV), and total lesion glycolysis (TLG) were calculated. Immunohistochemical analysis of PD-L1 expression and tumour-infiltrating lymphocytes was conducted. Results Among all patients, a partial metabolic response to nivolumab was observed in 29% on SUV max , 25% on MTV, and 33% on TLG, whereas seven (29%) patients achieved a partial response (PR) based on RECIST v1.1. The predictive probability of PR (100% vs. 29%, p = 0.021) and progressive disease (100% vs. 22.2%, p = 0.002) at 1 month after nivolumab initiation was significantly higher in 18 F-FDG on PET/CT than in CT scans. Multivariate analysis confirmed that 18 F-FDG uptake after administration of nivolumab was an independent prognostic factor. PD-L1 expression and nivolumab plasma concentration could not precisely predict the early therapeutic efficacy of nivolumab. Conclusion Metabolic response by 18 F-FDG was effective in predicting efficacy and survival at 1 month a…

Overview

Integrity signals

Registry

Crossref · 10.1007/s00259-017-3806-1

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 28 references

Cited by

See all 203

Metadata

Authors
Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., Hisada, T., Kitano, S., Obinata, H., Yokobori, T., Mori, K., Nishiyama, M., Tsushima, Y., & Asao, T.
Affiliations
  • Gunma University (JP)
  • Hidaka Hospital (JP)
  • Gunma University Hospital (JP)
  • National Cancer Center Hospital (JP)
  • Gunma University Initiative for Advanced Research (JP)
  • Shizuoka Cancer Center (JP)
Corresponding author
Kaira, Kyoichi
Venue
European Journal of Nuclear Medicine and Molecular Imaging
Published
2017-08-21
Volume
45
Issue
1
Pages
56-66
ISSN
  • 1619-7070 (ISSN-L)
  • 1619-7089
OpenAlex
W2749460173
Cited by
195
References
28
Citations by year
2026: 7 · 2025: 9 · 2024: 16 · 2023: 19 · 2022: 23 · 2021: 38 · 2020: 36 · 2019: 35 · 2018: 10 · 2017: 2
FWCI
10.00
Type
journal article
Language
en
Open access
closed
Licence
www.springer.com/tdm (tdm)
Locations
  • European Journal of Nuclear Medicine and Molecular Imaging (publishedVersion)
  • PubMed (publishedVersion)
Funders
Japan Society for the Promotion of Science (15K09945)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Medical Imaging Techniques and Applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Keywords
nivolumab, non-small cell lung cancer, 18F-FDG PET/CT, early treatment response prediction, PD-1 inhibitors, SUVmax, metabolic tumor volume, total lesion glycolysis, PD-L1 expression, tumor-infiltrating lymphocytes, prognostic factors
MeSH terms
Positron Emission Tomography Computed Tomography, Nivolumab, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Female, Humans, Lung Neoplasms, Male, Middle Aged, Predictive Value of Tests, Radiopharmaceuticals, Fluorodeoxyglucose F18

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC. https://app.cochat.ai/papers/10.1007/s00259-017-3806-1
The paper
Kaira, K., Higuchi, T., Naruse, I., Arisaka, Y., Tokue, A., Altan, B., Suda, S., Mogi, A., Shimizu, K., Sunaga, N., Hisada, T., Kitano, S., Obinata, H., Yokobori, T., Mori, K., Nishiyama, M., Tsushima, Y., & Asao, T. (2018). Metabolic Activity by 18F-FDG-PET/CT Is Predictive of Early Response after Nivolumab in Previously Treated NSCLC. European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-017-3806-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.